MedTrace Logo

Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent

NCT00544609 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2014-10-02

No results posted yet for this study

Summary

Safety profile and to determine maximum tolerated dose of Sorafenib in combination with Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent

Conditions

Interventions

DRUG

Sorafenib

Level 1: 200 mg/day Level 2: 400mg/day Level 3: 800mg/day

PROCEDURE

Radiotherapy

3th-8th week: sorafenib daily with radiotherapy day 1, 2, 3, 4 and 5, 9th week: sorafenib daily with radiotherapy day 1 and 2

Sponsors & Collaborators

  • Spanish Oncology Genito-Urinary Group

    lead OTHER

Principal Investigators

  • Xavier García del Muro Solans, MD · Institut Català d' Oncología, Barcelona

  • Salvador Villà Freixa, MD · Institut Català d' Oncología, Barcelona

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2010-08-31
Completion
2012-05-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00544609 on ClinicalTrials.gov